Market Overview

UPDATE: Jefferies Reiterates Hold Rating, Raises PT on ResMed

Share:
Related RMD
18 Biggest Mid-Day Losers For Wednesday
Benzinga's Top Upgrades, Downgrades For August 2, 2017
Resmed Shows Improved Relative Price Performance; Still Shy Of Benchmark (Investor's Business Daily)

In a report published Friday, Jefferies reiterated its Hold rating on ResMed (NYSE: RMD), and raised its price target from $35.00 to $42.00.

Jefferies noted, “RMD reported strong FQ2 results with revs and EPS beating by $13mm and $0.02. The upside was across the board, albeit off favorable year ago comps. Although we have clearly missed the ride, the tailwinds of HST & cardio adoption coupled with margin benefits from mix and Shanghai manufacturing are still blowing. That said, the stock is fully valued and Round II implementation in the US remains a hard to handicap risk keeping us at Hold.”

ResMed closed on Thursday at $45.47.

Latest Ratings for RMD

DateFirmActionFromTo
Aug 2017BMO CapitalMaintainsMarket Perform
Aug 2017CitigroupUpgradesNeutralBuy
Aug 2017Bank of AmericaDowngradesBuyNeutral

View More Analyst Ratings for RMD
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (RMD)

View Comments and Join the Discussion!